HC Wainwright Issues Pessimistic Estimate for GALT Earnings

Galectin Therapeutics Inc. (NASDAQ:GALT) – Analysts at HC Wainwright cut their FY2027 EPS estimates for shares of Galectin Therapeutics in a research report issued on Friday, November 15th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of $1.25 for the year, down from their previous forecast of $1.29. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ FY2028 earnings at $3.39 EPS.

Separately, StockNews.com lowered shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th.

Galectin Therapeutics Trading Down 2.9 %

GALT opened at $2.69 on Monday. The company has a market capitalization of $167.53 million, a price-to-earnings ratio of -3.68 and a beta of 0.62. Galectin Therapeutics has a 12-month low of $1.55 and a 12-month high of $4.27. The business’s fifty day simple moving average is $2.69 and its 200-day simple moving average is $2.61.

Institutional Trading of Galectin Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Commonwealth Equity Services LLC raised its position in shares of Galectin Therapeutics by 317.6% in the 2nd quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock worth $1,092,000 after acquiring an additional 367,610 shares in the last quarter. Soltis Investment Advisors LLC bought a new position in Galectin Therapeutics in the third quarter worth about $387,000. Sanctuary Advisors LLC purchased a new stake in shares of Galectin Therapeutics during the second quarter valued at about $227,000. Bank of New York Mellon Corp purchased a new stake in shares of Galectin Therapeutics during the second quarter valued at about $146,000. Finally, Kovitz Investment Group Partners LLC bought a new stake in shares of Galectin Therapeutics in the 3rd quarter valued at about $117,000. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.